1. | Application fee for, or for renewal of, a manufacturer’s licence for — |
|
| | |
(a) | manufacture of external preparations only |
|
| | |
(b) | manufacture of oral preparations only |
|
| | |
(c) | manufacture of external and oral preparations only |
|
| | |
(d) | manufacture of sterile preparations, or other types of dosage forms or dosage form combinations not described in paragraphs (a), (b) and (c) |
|
| | |
(e) | primary (with or without secondary) packaging |
|
| | |
(f) | secondary packaging only |
|
| | |
2. | Application fee for amending a manufacturer’s licence — |
|
| | |
(a) | without site inspection (administrative amendment) |
|
| | |
(b) | without site inspection (for a manufacturer carrying out packaging only) |
|
| | |
(c) | with site inspection (for a manufacturer carrying out packaging only) |
|
| | |
(d) | with site inspection (for all other manufacturers) |
|
| | |
3. | Application fee for, or for renewal of, an importer’s licence for — |
|
| | |
(a) | any therapeutic product |
|
| | |
(b) | any therapeutic product imported under one of the following regulations: |
|
| | |
(i) | regulation 5(1)(b)(ii) of the TP Regulations (for scientific education, etc.) |
|
| | |
(ii) | regulation 5(1)(b)(iii) of the TP Regulations (for export only) |
|
| | |
(iii) | regulation 5(1)(b)(iv) or (v) of the TP Regulations (for supply to a ship or an aircraft) |
|
| | |
4. | Application fee for an importer’s licence for a consignment of any therapeutic product imported under regulation 5(1)(b)(ii), (iii), (iv) or (v) of the TP Regulations |
|
| | |
5. | Application fee for amending an importer’s licence — |
|
| | |
(a) | without site inspection (administrative amendment) |
|
| | |
| | |
6. | Application fee for approval to import or export therapeutic products containing psychotropic substances |
|
| | |
7. | Application fee for approval to import registered therapeutic products under regulation 5(1)(b)(vii) of the TP Regulations |
|
| | |
8. | Application fee for, or for renewal of, a wholesaler’s licence for any therapeutic product |
|
| | |
9. | Application fee for amending a wholesaler’s licence — |
|
| | |
(a) | without site inspection (administrative amendment) |
|
| | |
| | |
10. | Application fee for, or for renewal of, an importer’s licence and a wholesaler’s licence for any therapeutic product |
|
| | |
11. | Registering one or more innovator products which have not yet been approved by any competent drug regulatory agency and for which the Authority will conduct a full evaluation: |
|
| | |
(a) | application fee for the initial screening |
|
| | |
| | |
12. | Registering an innovator product which is approved by at least one competent drug regulatory agency and for which the Authority will conduct an abridged evaluation: |
|
| | |
(a) | application fee for the initial screening (for each product) |
|
| | |
(b) | evaluation fee for a single‑strength product or the first product in a series of products of different strengths |
|
| | |
(c) | evaluation fee for each subsequent product in a series of products of different strengths |
|
| | |
13. | Registering an innovator product which is approved by any reference drug regulatory agency and for which the Authority will conduct a verification evaluation: |
|
| | |
(a) | application fee for the initial screening (for each product) |
|
| | |
(b) | evaluation fee for a single‑strength product or the first product in a series of products of different strengths |
|
| | |
(c) | evaluation fee for each subsequent product in a series of products of different strengths |
|
| | |
14. | Registering a generic drug product which is approved by at least one competent drug regulatory agency and for which the Authority will conduct an abridged evaluation: |
|
| | |
(a) | application fee for the initial screening (for each product) |
|
| | |
(b) | evaluation fee for a single‑strength product or the first product in a series of products of different strengths |
|
| | |
(c) | evaluation fee for each subsequent product in a series of products of different strengths |
|
| | |
15. | Registering a generic drug product which is approved by any reference drug regulatory agency and for which the Authority will conduct a verification evaluation under the Special Scheme for Registration of Generic Medicinal Products from India established pursuant to Chapter 5 of the India‑Singapore Comprehensive Economic Cooperation Agreement: |
|
| | |
(a) | application fee for the initial screening (for each product) |
|
| | |
(b) | evaluation fee for a single‑strength product or the first product in a series of products of different strengths |
|
| | |
(c) | evaluation fee for each subsequent product in a series of products of different strengths |
|
| | |
16. | Registering a generic drug product which is approved by any reference drug regulatory agency and for which the Authority will conduct a verification evaluation: |
|
| | |
(a) | application fee for the initial screening (for each product) |
|
| | |
(b) | evaluation fee for a single‑strength product or the first product in a series of products of different strengths |
|
| | |
(c) | evaluation fee for each subsequent product in a series of products of different strengths |
|
| | |
17. | Fees, in addition to the fees in item 11, 12, 13, 14, 15 or 16 (as the case may be) for overseas manufacturers: |
|
| | |
(a) | application fee for verification of Good Manufacturing Practice Standard |
|
| | |
(b) | evaluation fee for Quality System Dossier |
|
| | |
(c) | evaluation fee for on‑site audit — |
|
| | |
| | |
(ii) | in a non‑ASEAN country in Asia |
|
| | |
| | |
18. | Registration fee for a therapeutic product |
|
| | |
19. | Annual retention fee for the retention of the registration of a therapeutic product |
|
| | |
20. | For the Authority’s approval — |
|
| | |
(a) | to make a major variation to a registered therapeutic product, for which the Authority will conduct a full evaluation — |
|
| | |
(i) | application fee for the initial screening for a series of products of the same proprietary name |
|
| | |
(ii) | evaluation fee for a series of products of the same proprietary name |
|
| | |
(b) | to make a major variation to a registered therapeutic product, for which the Authority will conduct an abridged evaluation — |
|
| | |
(i) | application fee for the initial screening (for each product) |
|
| | |
(ii) | evaluation fee for a single‑strength product or the first product in a series of products of different strengths |
|
| | |
(iii) | evaluation fee for each subsequent product in a series of products of different strengths |
|
| | |
(c) | to make a major variation to a registered therapeutic product, for which the Authority will conduct a verification evaluation — |
|
| | |
(i) | application fee for the initial screening (for each product) |
|
| | |
(ii) | evaluation fee for a single‑strength product or the first product in a series of products of different strengths |
|
| | |
(iii) | evaluation fee for each subsequent product in a series of products of different strengths |
|
| | |
21. | Application fee for the Authority’s approval to make any other variations to a registered therapeutic product where such approval is required (excluding applications to change the forensic classification of the product) |
|
| | |
22. | Application fee for the following certificates or documents: |
|
| | |
| | |
(b) | each additional copy of a GMP Certificate |
|
| | |
| | |
(d) | each additional copy of a GDP Certificate |
|
| | |
(e) | certificate of registration or compliance under regulation 61 of the TP Regulations for a therapeutic product intended for export |
|
| | |
(f) | certificate of approval under regulation 64 of the TP Regulations for import of a therapeutic product into Singapore |
|
| | |